BRAF-targeted strategies and PD-1–blocking immunotherapy are more effective adjuvant therapies than currently approved options for patients with high-risk resectable melanoma. However, choosing the best agent for patients with BRAF-mutated disease remains a challenge.
http://ift.tt/2iSMt0l
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου